

# Jörg Ellinger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5996906/publications.pdf>

Version: 2024-02-01

167  
papers

6,840  
citations

53794

45  
h-index

76900

74  
g-index

188  
all docs

188  
docs citations

188  
times ranked

8925  
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA-profiling of miR-371~373- and miR-302/367-clusters in serum and cerebrospinal fluid identify patients with intracranial germ cell tumors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 791-802.	2.5	9
2	Comprehensive immunohistochemical analysis of N6-methyladenosine (m6A) writers, erasers, and readers in endometrial cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2417-2424.	2.5	5
3	<sup>177</sup> Lu-Prostate-Specific Membrane Antigen Ligand After <sup>223</sup> Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience. <i>Journal of Nuclear Medicine</i> , 2022, 63, 410-414.	5.0	19
4	Systemic Effects Reflected in Specific Biomarker Patterns Are Instrumental for the Paradigm Change in Prostate Cancer Management: A Strategic Paper. <i>Cancers</i> , 2022, 14, 675.	3.7	10
5	Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort. <i>Urologia Internationalis</i> , 2022, 106, 1150-1157.	1.3	5
6	C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer. , 2022, 10, e004024.		38
7	CD103+ Tissue Resident T-Lymphocytes Accumulate in Lung Metastases and Are Correlated with Poor Prognosis in ccRCC. <i>Cancers</i> , 2022, 14, 1541.	3.7	6
8	C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma. <i>European Journal of Cancer</i> , 2022, 167, 13-22.	2.8	15
9	RNA Sequencing Reveals Alterations and Similarities in Cell Metabolism, Hypoxia and Immune Evasion in Primary Cell Cultures of Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, .	2.8	0
10	Comprehensive Analysis of N6-Methyladenosine (m6A) Writers, Erasers, and Readers in Cervical Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7165.	4.1	6
11	Otoferlin is a prognostic biomarker in patients with clear cell renal cell carcinoma: A systematic expression analysis. <i>International Journal of Urology</i> , 2021, 28, 424-431.	1.0	6
12	Prognostic role of TSPAN1, KIAA1324 and ESRP1 in prostate cancer. <i>Apmis</i> , 2021, 129, 204-212.	2.0	16
13	N <sup>6</sup> -Methyladenosine (m <sup>6</sup> A) readers are dysregulated in renal cell carcinoma. <i>Molecular Carcinogenesis</i> , 2021, 60, 354-362.	2.7	19
14	DNA Promoter Methylation and ERG Regulate the Expression of CD24 in Prostate Cancer. <i>American Journal of Pathology</i> , 2021, 191, 618-630.	3.8	7
15	CircEHD2, CircNETO2 and CircEGLN3 as Diagnostic and Prognostic Biomarkers for Patients with Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 2177.	3.7	18
16	Systematic expression analysis of m <sup>6</sup> A RNA methyltransferases in clear cell renal cell carcinoma. <i>BJUI Compass</i> , 2021, 2, 402-411.	1.3	8
17	Pelvic Exenteration in Advanced Gynecologic Malignancies – Who Will Benefit?. <i>Anticancer Research</i> , 2021, 41, 3037-3043.	1.1	4
18	CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma. , 2021, 9, e002949.		22

#	ARTICLE	IF	CITATIONS
19	A Multi-institutional Pooled Analysis Demonstrates That Circulating miR-371a-3p Alone is Sufficient for Testicular Malignant Germ Cell Tumor Diagnosis. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 469-479.	1.9	19
20	C-reactive protein flare response predicts long-term efficacy to first-line anti-PD-1 based combination therapy in metastatic renal cell carcinoma. <i>Clinical and Translational Immunology</i> , 2021, 10, e1358.	3.8	15
21	Comprehensive Analysis of the ATP-binding Cassette Subfamily B Across Renal Cancers Identifies ABCB8 Overexpression in Phenotypically Aggressive Clear Cell Renal Cell Carcinoma. <i>European Urology Focus</i> , 2020, 7, 1121-1129.	3.1	6
22	Cultivation of Clear Cell Renal Cell Carcinoma Patient-Derived Organoids in an Air-Liquid Interface System as a Tool for Studying Individualized Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 1775.	2.8	24
23	Identification of miR-21-5p and miR-210-3p serum levels as biomarkers for patients with papillary renal cell carcinoma: a multicenter analysis. <i>Translational Andrology and Urology</i> , 2020, 9, 1314-1322.	1.4	10
24	Downstream Neighbor of SON (DONSON) Expression Is Enhanced in Phenotypically Aggressive Prostate Cancers. <i>Cancers</i> , 2020, 12, 3439.	3.7	7
25	Mitophagy-associated genes PINK1 and PARK2 are independent prognostic markers of survival in papillary renal cell carcinoma and associated with aggressive tumor behavior. <i>Scientific Reports</i> , 2020, 10, 18857.	3.3	5
26	Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2471.	3.7	20
27	Downstream neighbor of SON (DONSON) is associated with unfavorable survival across diverse cancers with oncogenic properties in clear cell renal cell carcinoma. <i>Translational Oncology</i> , 2020, 13, 100844.	3.7	8
28	The contrasting roles of Dysferlin during tumor progression in renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 687.e1-687.e11.	1.6	4
29	Targeting glycolysis with 2-deoxy-d-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2255-2265.	2.5	10
30	The lncRNA Fer1L4 is an adverse prognostic parameter in clear-cell renal-cell carcinoma. <i>Clinical and Translational Oncology</i> , 2020, 22, 1524-1531.	2.4	15
31	The N <sup>6</sup> -methyladenosine (m <sup>6</sup> A) erasers alkylolation repair homologue 5 (ALKBH5) and fat mass and obesity-associated protein (FTO) are prognostic biomarkers in patients with clear cell renal carcinoma. <i>BJU International</i> , 2020, 125, 617-624.	2.5	65
32	LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma. , 2020, 8, e000552.		70
33	Disease characteristics and outcome of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received a beta emitter (177Lu-PSMA) after an alpha emitter (radium-223).. <i>Journal of Clinical Oncology</i> , 2020, 38, e17592-e17592.	1.6	2
34	DNA Methylation and Bladder Cancer: Where Genotype does not Predict Phenotype. <i>Current Genomics</i> , 2020, 21, 34-36.	1.6	17
35	ITIH5 and ECRG4 DNA Methylation Biomarker Test (EI-BLA) for Urine-Based Non-Invasive Detection of Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1117.	4.1	18
36	Low Plasma Appearance of (+)-Catechin and (–)-Catechin Compared with Epicatechin after Consumption of Beverages Prepared from Nonalkalized or Alkalized Cocoa—A Randomized, Double-Blind Trial. <i>Nutrients</i> , 2020, 12, 231.	4.1	11

#	ARTICLE	IF	CITATIONS
37	Classic bladder exstrophy and adenocarcinoma of the bladder: Methylome analysis provide no evidence for underlying disease-mechanisms of this association. <i>Cancer Genetics</i> , 2019, 235-236, 18-20.	0.4	10
38	Systematic expression analysis of the mitochondrial respiratory chain protein subunits identifies COX5B as a prognostic marker in clear cell renal cell carcinoma. <i>International Journal of Urology</i> , 2019, 26, 910-916.	1.0	10
39	Evaluation of Serum Biomarkers (FGF-2, HGF, MIF and PTN) in Patients With Testicular Germ Cell Cancer. <i>In Vivo</i> , 2019, 33, 1935-1940.	1.3	4
40	Apelin and apelin receptor expression in renal cell carcinoma. <i>British Journal of Cancer</i> , 2019, 120, 633-639.	6.4	22
41	Mitochondrial PIWI-interacting RNAs are novel biomarkers for clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2019, 37, 1639-1647.	2.2	22
42	Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e167-e175.	1.9	10
43	Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study. <i>Clinical Chemistry</i> , 2019, 65, 559-568.	3.2	17
44	YRNA expression in prostate cancer patients: diagnostic and prognostic implications. <i>World Journal of Urology</i> , 2018, 36, 1073-1078.	2.2	17
45	The knockdown of the mediator complex subunit MED30 suppresses the proliferation and migration of renal cell carcinoma cells. <i>Annals of Diagnostic Pathology</i> , 2018, 34, 18-26.	1.3	4
46	Fungaemia caused by obstructive renal candida bezoars leads to bilateral chorioretinitis: a case report. <i>BMC Urology</i> , 2018, 18, 21.	1.4	3
47	Influence of Body Mass Index on Clinical Outcome Parameters, Complication Rate and Survival after Radical Cystectomy: Evidence from a Prospective European Multicentre Study. <i>Urologia Internationalis</i> , 2018, 101, 16-24.	1.3	28
48	The Mediator complex subunit MED15, a promoter of tumour progression and metastatic spread in renal cell carcinoma. <i>Cancer Biomarkers</i> , 2018, 21, 839-847.	1.7	9
49	YRNA Expression Profiles are Altered in Clear Cell Renal Cell Carcinoma. <i>European Urology Focus</i> , 2018, 4, 260-266.	3.1	18
50	Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. <i>Journal of Urology</i> , 2018, 199, 370-377.	0.4	71
51	5â€²-tRNA Halves are Dysregulated in Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2018, 199, 378-383.	0.4	43
52	tRNA-halves are prognostic biomarkers for patients with prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 503.e1-503.e7.	1.6	25
53	Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma. <i>Clinical Epigenetics</i> , 2018, 10, 11.	4.1	87
54	The knockdown of the Mediator complex subunit MED15 restrains urothelial bladder cancer cells' malignancy. <i>Oncology Letters</i> , 2018, 16, 3013-3021.	1.8	4

#	ARTICLE	IF	CITATIONS
55	ISL1 is a major susceptibility gene for classic bladder exstrophy and a regulator of urinary tract development. <i>Scientific Reports</i> , 2017, 7, 42170.	3.3	41
56	Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study. <i>Clinical Chemistry</i> , 2017, 63, 1288-1296.	3.2	97
57	Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e809-e817.	1.9	21
58	PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 107-114.	2.8	41
59	Systematic Expression Analysis of Mitochondrial Complex I Identifies NDUFS1 as a Biomarker in Clear-Cell Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e551-e562.	1.9	23
60	High grade adenocarcinoma in the ectopic prostate accompanied by a low grade adenocarcinoma in the orthotopic prostate: an unusual diagnostic pitfall. <i>Pathology</i> , 2017, 49, 665-668.	0.6	2
61	Systematic Analysis of the Expression of the Mitochondrial ATP Synthase (Complex V) Subunits in Clear Cell Renal Cell Carcinoma. <i>Translational Oncology</i> , 2017, 10, 661-668.	3.7	48
62	Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression. <i>Frontiers in Medicine</i> , 2017, 4, 30.	2.6	13
63	YRNA expression predicts survival in bladder cancer patients. <i>BMC Cancer</i> , 2017, 17, 749.	2.6	25
64	Loss of cadherin related family member 5 (CDHR5) expression in clear cell renal cell carcinoma is a prognostic marker of disease progression. <i>Oncotarget</i> , 2017, 8, 75076-75086.	1.8	10
65	The Contrasting Role of the Mediator Subunit MED30 in the Progression of Bladder Cancer. <i>Anticancer Research</i> , 2017, 37, 6685-6695.	1.1	4
66	<i>CXCL12</i> promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients. <i>Oncotarget</i> , 2016, 7, 53309-53320.	1.8	37
67	<i>PD-L1</i> promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. <i>Oncotarget</i> , 2016, 7, 79943-79955.	1.8	73
68	Identification of aberrant tRNA-halves expression patterns in clear cell renal cell carcinoma. <i>Scientific Reports</i> , 2016, 6, 37158.	3.3	59
69	Testicular seminoma clinical stage 1: treatment outcome on a routine care level. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1599-1607.	2.5	48
70	Seminoma Clinical Stage 1 - Patterns of Care in Germany. <i>Urologia Internationalis</i> , 2016, 96, 390-398.	1.3	15
71	Promoter methylation of the immune checkpoint receptor <i>PD-1</i> ( <i>PDCD1</i> ) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. <i>Oncolmmunology</i> , 2016, 5, e1221555.	4.6	43
72	<i>CDO1</i> promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients. <i>Epigenetics</i> , 2016, 11, 871-880.	2.7	37

#	ARTICLE	IF	CITATIONS
73	The emerging role of non-coding circulating RNA as a biomarker in renal cell carcinoma. Expert Review of Molecular Diagnostics, 2016, 16, 1059-1065.	3.1	19
74	PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy. Clinical Epigenetics, 2016, 8, 104.	4.1	16
75	Primary Urethral Plasmacytoma Treated with High-Dose-Rate Brachytherapy: A Case Report. Urologia Internationalis, 2016, 97, 369-372.	1.3	0
76	Cytoplasmatic and Nuclear YAP1 and pYAP1 Staining in Urothelial Bladder Cancer. Urologia Internationalis, 2016, 96, 39-45.	1.3	4
77	Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma. Molecular Cancer, 2016, 15, 10.	19.2	53
78	The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. Clinical Cancer Research, 2016, 22, 1969-1977.	7.0	170
79	Systematic expression analysis of the mitochondrial complex III subunits identifies UQCRC1 as biomarker in clear cell renal cell carcinoma. Oncotarget, 2016, 7, 86490-86499.	1.8	26
80	Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types. Oncotarget, 2016, 7, 23043-23055.	1.8	24
81	Evaluation of Global Histone Acetylation Levels in Bladder Cancer Patients. Anticancer Research, 2016, 36, 3961-4.	1.1	16
82	Differential expression of Mediator complex subunit MED15 in testicular germ cell tumors. Diagnostic Pathology, 2015, 10, 165.	2.0	11
83	Evidence from the â€˜PROspective MulticEnTer Radical Cystectomy Series 2011 (PROMETRICS 2011)â€™ Study: How are Preoperative Patient Characteristics Associated with Urinary Diversion Type After Radical Cystectomy for Bladder Cancer?. Annals of Surgical Oncology, 2015, 22, 1032-1042.	1.5	33
84	Epigenetic biomarkers in the blood of patients with urological malignancies. Expert Review of Molecular Diagnostics, 2015, 15, 505-516.	3.1	54
85	Identification of novel differentially expressed lncRNA and mRNA transcripts in clear cell renal cell carcinoma by expression profiling. Genomics Data, 2015, 5, 173-175.	1.3	32
86	Identification of novel long non-coding RNAs in clear cell renal cell carcinoma. Clinical Epigenetics, 2015, 7, 10.	4.1	77
87	Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentapecta. World Journal of Urology, 2015, 33, 1945-1950.	2.2	28
88	Circulating Serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as Biomarkers in Patients with Testicular Germ Cell Cancer. Journal of Urology, 2015, 193, 331-337.	0.4	169
89	Analysis of Tissue and Serum MicroRNA Expression in Patients with Upper Urinary Tract Urothelial Cancer. PLoS ONE, 2015, 10, e0117284.	2.5	42
90	The long non-coding RNA lnc-ZNF180-2 is a prognostic biomarker in patients with clear cell renal cell carcinoma. American Journal of Cancer Research, 2015, 5, 2799-807.	1.4	31

#	ARTICLE	IF	CITATIONS
91	NDUFA4 expression in clear cell renal cell carcinoma is predictive for cancer-specific survival. American Journal of Cancer Research, 2015, 5, 2816-22.	1.4	8
92	Prognostic significance of venous tumour thrombus consistency in patients with renal cell carcinoma (<scp>RCC</scp>). BJU International, 2014, 113, 209-217.	2.5	26
93	Diagnostic Meaning of Urodynamic Studies in Pouch Incontinence: Results of a Small Series. Urologia Internationalis, 2014, 92, 237-241.	1.3	2
94	Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation. World Journal of Urology, 2014, 32, 365-371.	2.2	3
95	Alterations of Global Histone H3K9 and H3K27 Methylation Levels in Bladder Cancer. Urologia Internationalis, 2014, 93, 113-118.	1.3	31
96	Nucleic acid-based tissue biomarkers of urologic malignancies. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 173-199.	6.1	33
97	KDM5C Is Overexpressed in Prostate Cancer and Is a Prognostic Marker for Prostate-Specific Antigen-Relapse Following Radical Prostatectomy. American Journal of Pathology, 2014, 184, 2430-2437.	3.8	69
98	Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer?. World Journal of Urology, 2014, 32, 353-358.	2.2	108
99	MicroRNAs: A Novel Non-Invasive Biomarker for Patients with Urological Malignancies. Current Pharmaceutical Biotechnology, 2014, 15, 486-491.	1.6	7
100	Programmed Cell Death Protein 4 -Expression in Urologic Tumors. The Open Prostate Cancer Journal, 2014, 7, 7-11.	0.4	0
101	Diagnostic und Therapeutic Value of Cell-free Circulating DNA as a Non-invasive Biomarker in Patients with Prostate Cancer. Current Cancer Therapy Reviews, 2014, 9, 258-264.	0.3	1
102	Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer. American Journal of Cancer Research, 2014, 4, 952-62.	1.4	9
103	Serum microRNAs as biomarkers in patients undergoing prostate biopsy: results from a prospective multi-center study. Anticancer Research, 2014, 34, 665-9.	1.1	37
104	Epigenetic regulation of microRNA expression in renal cell carcinoma. Biochemical and Biophysical Research Communications, 2013, 436, 79-84.	2.1	18
105	Spindle cell rhabdomyosarcoma of the prostate. International Journal of Urology, 2013, 20, 935-937.	1.0	7
106	Prediction of outcome in patients with urothelial carcinoma of the bladder following radical cystectomy using artificial neural networks. European Journal of Surgical Oncology, 2013, 39, 372-379.	1.0	20
107	Histone Methylation Defines an Epigenetic Entity in Penile Squamous Cell Carcinoma. Journal of Urology, 2013, 189, 1117-1122.	0.4	10
108	Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1141-1147.	1.6	55

#	ARTICLE	IF	CITATIONS
109	Serum DNA hypermethylation in patients with bladder cancer: results of a prospective multicenter study. <i>Anticancer Research</i> , 2013, 33, 779-84.	1.1	24
110	Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study. <i>Anticancer Research</i> , 2013, 33, 4651-6.	1.1	43
111	The peripheral zone of the prostate is more prone to tumor development than the transitional zone: Is the ETS family the key?. <i>Molecular Medicine Reports</i> , 2012, 5, 313-6.	2.4	41
112	Thulium Laser (Revolix) Vapoenucleation of the Prostate Is a Safe Procedure in Patients with an Increased Risk of Hemorrhage. <i>Urologia Internationalis</i> , 2012, 88, 390-394.	1.3	39
113	Rationale for Treatment of Metastatic Squamous Cell Carcinoma of the Lung Using Fibroblast Growth Factor Receptor Inhibitors. <i>Chest</i> , 2012, 142, 1020-1026.	0.8	47
114	Bolus Consumption of a Specifically Designed Fruit Juice Rich in Anthocyanins and Ascorbic Acid Did Not Influence Markers of Antioxidative Defense in Healthy Humans. <i>Journal of Agricultural and Food Chemistry</i> , 2012, 60, 11292-11300.	5.2	19
115	Tyrosine kinase expression profile in clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2012, 30, 559-565.	2.2	38
116	External Validation of a Risk Model to Predict Recurrence-Free Survival After Radical Cystectomy in Patients With Pathological Tumor Stage T3N0 Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2012, 187, 1210-1214.	0.4	7
117	Circulating mitochondrial DNA in serum: A universal diagnostic biomarker for patients with urological malignancies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 509-515.	1.6	90
118	Global Histone H3K27 Methylation Levels are Different in Localized and Metastatic Prostate Cancer. <i>Cancer Investigation</i> , 2012, 30, 92-97.	1.3	51
119	Expression of programmed cell death protein 4 (PDCD4) and miR-21 in urothelial carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2012, 417, 29-34.	2.1	11
120	External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial carcinoma of the bladder. <i>European Journal of Surgical Oncology</i> , 2012, 38, 637-642.	1.0	11
121	Kinetics of $\gamma$ -Theanine Uptake and Metabolism in Healthy Participants Are Comparable after Ingestion of $\gamma$ -Theanine via Capsules and Green Tea <sup>4</sup> . <i>Journal of Nutrition</i> , 2012, 142, 2091-2096.	2.9	43
122	Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. <i>Cancer Epidemiology</i> , 2012, 36, 391-394.	1.9	101
123	Analysis of Sex Differences in Cancer-Specific Survival and Perioperative Mortality Following Radical Cystectomy: Results of a Large German Multicenter Study of Nearly 2500 Patients with Urothelial Carcinoma of the Bladder. <i>Gender Medicine</i> , 2012, 9, 481-489.	1.4	65
124	Identification of prostaglandin receptors in human ureters. <i>BMC Urology</i> , 2012, 12, 35.	1.4	5
125	Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma. <i>BJU International</i> , 2012, 109, 459-465.	2.5	58
126	Pathological Outcomes of Men Eligible for Active Surveillance After Undergoing Radical Prostatectomy: Are Results Predictable?. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 32-36.	1.9	5



#	ARTICLE	IF	CITATIONS
127	Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. <i>International Journal of Urology</i> , 2012, 19, 1017-1025.	1.0	84
128	Alterations of global histone H4K20 methylation during prostate carcinogenesis. <i>BMC Urology</i> , 2012, 12, 5.	1.4	46
129	Decreased levels of histone H3K9me1 indicate poor prognosis in patients with renal cell carcinoma. <i>Anticancer Research</i> , 2012, 32, 879-86.	1.1	25
130	Enhanced expression of peroxisome proliferate-activated receptor gamma (PPAR- $\gamma$ ) in advanced prostate cancer. <i>Anticancer Research</i> , 2012, 32, 3479-83.	1.1	28
131	Glutathione-S-transferase pi 1 (GSTP1) gene silencing in prostate cancer cells is reversed by the histone deacetylase inhibitor depsipeptide. <i>Biochemical and Biophysical Research Communications</i> , 2011, 412, 606-611.	2.1	11
132	Circulating microRNAs (miRNA) in Serum of Patients With Prostate Cancer. <i>Urology</i> , 2011, 77, 1265.e9-1265.e16.	1.0	210
133	Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer. <i>BJU International</i> , 2011, 108, E290-E296.	2.5	68
134	The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 124-129.	1.6	47
135	Genes differentially expressed in the peripheral zone compared to the transitional zone of the normal human prostate and their potential regulation by ETS factors. <i>Molecular Medicine Reports</i> , 2011, 5, 32-6.	2.4	5
136	Identification of immunity-related genes in prostate cancer and potential role of the ETS family of transcription factors in their regulation. <i>International Journal of Molecular Medicine</i> , 2011, 28, 799-807.	4.0	5
137	DNA hypermethylation in papillary renal cell carcinoma. <i>BJU International</i> , 2011, 107, 664-669.	2.5	25
138	Multicenter evaluation of the prognostic value of pT0 stage after radical cystectomy due to urothelial carcinoma of the bladder. <i>BJU International</i> , 2011, 108, E278-E283.	2.5	16
139	Lymph Node Density Affects Cancer-Specific Survival in Patients with Lymph Node-Positive Urothelial Bladder Cancer Following Radical Cystectomy. <i>European Urology</i> , 2011, 59, 712-718.	1.9	76
140	Association Between the Number of Dissected Lymph Nodes During Pelvic Lymphadenectomy and Cancer-Specific Survival in Patients with Lymph Node-Negative Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2011, 18, 2018-2025.	1.5	112
141	Comparison of Myocardial Remodeling between Cryoinfarction and Reperfused Infarction in Mice. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-10.	3.0	17
142	Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder. <i>Scandinavian Journal of Urology and Nephrology</i> , 2011, 45, 251-257.	1.4	20
143	MicroRNAs in Renal Cell Carcinoma: Diagnostic Implications of Serum miR-1233 Levels. <i>PLoS ONE</i> , 2011, 6, e25787.	2.5	202
144	Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. <i>International Journal of Cancer</i> , 2010, 127, 2360-2366.	5.1	101

#	ARTICLE	IF	CITATIONS
145	Global levels of histone modifications predict prostate cancer recurrence. <i>Prostate</i> , 2010, 70, 61-69.	2.3	194
146	Global histone acetylation levels: Prognostic relevance in patients with renal cell carcinoma. <i>Cancer Science</i> , 2010, 101, 2664-2669.	3.9	84
147	H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1. <i>Human Pathology</i> , 2010, 41, 181-189.	2.0	93
148	Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel noninvasive diagnostic biomarker. <i>BJU International</i> , 2009, 104, 48-52.	2.5	84
149	Saturation biopsy improves preoperative Gleason scoring of prostate cancer. <i>Pathology Research and Practice</i> , 2009, 205, 259-264.	2.3	11
150	Cell-Free Circulating DNA: Diagnostic Value in Patients With Testicular Germ Cell Cancer. <i>Journal of Urology</i> , 2009, 181, 363-371.	0.4	79
151	CpG Island Hypermethylation of Cell-Free Circulating Serum DNA in Patients With Testicular Cancer. <i>Journal of Urology</i> , 2009, 182, 324-329.	0.4	77
152	CpG Island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. <i>Prostate</i> , 2008, 68, 42-49.	2.3	121
153	Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. <i>International Journal of Cancer</i> , 2008, 122, 138-143.	5.1	87
154	First report of an unexpected blind-ending duplication of the ureter as a rare pitfall in kidney transplantation. <i>Transplant International</i> , 2008, 21, 696-697.	1.6	0
155	Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy. <i>BJU International</i> , 2008, 102, 628-632.	2.5	81
156	Soy isoflavone genistein in prevention and treatment of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2008, 11, 6-12.	3.9	115
157	Stem cell marker expression in small cell lung carcinoma and developing lung tissue. <i>Human Pathology</i> , 2008, 39, 1597-1605.	2.0	47
158	CpG Island Hypermethylation at Multiple Gene Sites in Diagnosis and Prognosis of Prostate Cancer. <i>Urology</i> , 2008, 71, 161-167.	1.0	120
159	Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: A prognostic entity. <i>Cancer Letters</i> , 2008, 264, 274-280.	7.2	61
160	Hypermethylation of Cell-Free Serum DNA Indicates Worse Outcome in Patients With Bladder Cancer. <i>Journal of Urology</i> , 2008, 179, 346-352.	0.4	66
161	A NOVEL DIAGNOSTIC MARKER: CELL-FREE CIRCULATING DNA IN SERUM OF PATIENTS WITH TESTICULAR CANCER. <i>Journal of Urology</i> , 2008, 179, 272-272.	0.4	0
162	HYPERMETHYLATION IN CELL-FREE CIRCULATING SERUM DNA IDENTIFIES PATIENTS WITH LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 2008, 179, 720-721.	0.4	0

#	ARTICLE	IF	CITATIONS
163	Prognostic Value of CpG Island Hypermethylation at PTGS2, RAR-beta, EDNRB, and Other Gene Loci in Patients Undergoing Radical Prostatectomy. <i>European Urology</i> , 2007, 51, 665-674.	1.9	72
164	Primitive neuroectodermal tumor: Rare, highly aggressive differential diagnosis in urologic malignancies. <i>Urology</i> , 2006, 68, 257-262.	1.0	109
165	Tomatoes, tomato products and lycopene in the prevention and treatment of prostate cancer: do we have the evidence from intervention studies?. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2006, 9, 722-727.	2.5	46
166	Androgen Receptor Coactivators Lysine-Specific Histone Demethylase 1 and Four and a Half LIM Domain Protein 2 Predict Risk of Prostate Cancer Recurrence. <i>Cancer Research</i> , 2006, 66, 11341-11347.	0.9	437
167	Diagnostic and Prognostic Information in Prostate Cancer with the Help of a Small Set of Hypermethylated Gene Loci. <i>Clinical Cancer Research</i> , 2005, 11, 4097-4106.	7.0	135